Regen BioPharma, Inc.
RGBP · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0.4% | 37.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 78.8% | 85.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $0 |
| Operating Income | -$0 | -$1 | -$0 | -$0 |
| % Margin | -176.3% | -290.4% | -144.4% | -117.4% |
| Other Income/Exp. Net | -$0 | $2 | $3 | -$7 |
| Pre-Tax Income | -$1 | $1 | $2 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | $1 | $2 | -$7 |
| % Margin | -282.4% | 432.9% | 945.6% | -3,951.7% |
| EPS | -0.16 | 0.14 | 0.36 | -1.69 |
| % Growth | -214.3% | -61.1% | 121.3% | – |
| EPS Diluted | -0.16 | 0.14 | 0.36 | -1.69 |
| Weighted Avg Shares Out | 4 | 7 | 3 | 2 |
| Weighted Avg Shares Out Dil | 4 | 7 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $2 | $0 | $0 |
| EBITDA | -$0 | $3 | $3 | -$6 |
| % Margin | -176.7% | 1,318.5% | 1,270.8% | -3,620% |